{"pmid":32435272,"pmcid":"PMC7224342","title":"Clinical characteristics of 9 cancer patients with SARS-CoV-2 infection.","text":["Clinical characteristics of 9 cancer patients with SARS-CoV-2 infection.","In December 2019, a cluster of pneumonia cases was caused by the Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) in Wuhan, China. Cancer patients are a special group, the immunity of them will be suppressed because of various anti-tumor treatments, and the risk of infection will be greatly increased, so we will report clinical features of 9 cancer patients with SARS-CoV-2 infection. 5 (56%) patients were ordinary type, 3 (33%) were severe type, and 1 (11%) was critical type. A total of 8 patients received combined therapy of traditional Chinese medicines and western medicines. From the clinical outcomes of these 8 patients, western combined therapy of traditional Chinese medicine was indeed an effective treatment method. D-dimmer rise, infection index rise, and chest CT(computed tomography) progression may be clinical warning indicators for severe patients, in our study, more 50% of patients had elevated levels of these indicators, but only 44% (including the dead) of patients had received treatment in the intensive care unit. 5 (56%) ordinary type patients had been discharged, while the 1 (11%) critical type patient died 3 days after admission. Cancer comorbidity seems to have no direct relationship with severe events, and the combination of traditional Chinese medicine and western medicine may be effective in the prevention and treatment of novel coronavirus-infected pneumonia (NICP).","Chin Med","Zeng, Yong","Zhang, Bo","Zhang, Xufeng","Yi, Cunjian","32435272"],"abstract":["In December 2019, a cluster of pneumonia cases was caused by the Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) in Wuhan, China. Cancer patients are a special group, the immunity of them will be suppressed because of various anti-tumor treatments, and the risk of infection will be greatly increased, so we will report clinical features of 9 cancer patients with SARS-CoV-2 infection. 5 (56%) patients were ordinary type, 3 (33%) were severe type, and 1 (11%) was critical type. A total of 8 patients received combined therapy of traditional Chinese medicines and western medicines. From the clinical outcomes of these 8 patients, western combined therapy of traditional Chinese medicine was indeed an effective treatment method. D-dimmer rise, infection index rise, and chest CT(computed tomography) progression may be clinical warning indicators for severe patients, in our study, more 50% of patients had elevated levels of these indicators, but only 44% (including the dead) of patients had received treatment in the intensive care unit. 5 (56%) ordinary type patients had been discharged, while the 1 (11%) critical type patient died 3 days after admission. Cancer comorbidity seems to have no direct relationship with severe events, and the combination of traditional Chinese medicine and western medicine may be effective in the prevention and treatment of novel coronavirus-infected pneumonia (NICP)."],"journal":"Chin Med","authors":["Zeng, Yong","Zhang, Bo","Zhang, Xufeng","Yi, Cunjian"],"date":"2020-05-22T11:00:00Z","year":2020,"_id":"32435272","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1186/s13020-020-00328-8","keywords":["cancer","clinical characteristics","outcomes","sars-cov-2"],"locations":["Wuhan","China","Chinese","Chinese","Chinese"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment","Diagnosis"],"weight":1,"_version_":1667521393712955392,"score":9.490897,"similar":[{"pmid":32198776,"title":"Clinical features and treatment of COVID-19 patients in northeast Chongqing.","text":["Clinical features and treatment of COVID-19 patients in northeast Chongqing.","The outbreak of the novel coronavirus in China (SARS-CoV-2) that began in December 2019 presents a significant and urgent threat to global health. This study was conducted to provide the international community with a deeper understanding of this new infectious disease. Epidemiological, clinical features, laboratory findings, radiological characteristics, treatment, and clinical outcomes of 135 patients in northeast Chongqing were collected and analyzed in this study. A total of 135 hospitalized patients with COVID-19 were enrolled. The median age was 47 years (interquartile range, 36-55), and there was no significant gender difference (53.3% men). The majority of patients had contact with people from the Wuhan area. Forty-three (31.9%) patients had underlying disease, primarily hypertension (13 [9.6%]), diabetes (12 [8.9%]), cardiovascular disease (7 [5.2%]), and malignancy (4 [3.0%]). Common symptoms included fever (120 [88.9%]), cough (102 [76.5%]), and fatigue (44 [32.5%]). Chest computed tomography scans showed bilateral patchy shadows or ground glass opacity in the lungs of all the patients. All patients received antiviral therapy (135 [100%]) (Kaletra and interferon were both used), antibacterial therapy (59 [43.7%]), and corticosteroids (36 [26.7%]). In addition, many patients received traditional Chinese medicine (TCM) (124 [91.8%]). It is suggested that patients should receive Kaletra early and should be treated by a combination of Western and Chinese medicines. Compared to the mild cases, the severe ones had lower lymphocyte counts and higher plasma levels of Pt, APTT, d-dimer, lactate dehydrogenase, PCT, ALB, C-reactive protein, and aspartate aminotransferase. This study demonstrates the clinic features and therapies of 135 COVID-19 patients. Kaletra and TCM played an important role in the treatment of the viral pneumonia. Further studies are required to explore the role of Kaletra and TCM in the treatment of COVID-19.","J Med Virol","Wan, Suxin","Xiang, Yi","Fang, Wei","Zheng, Yu","Li, Boqun","Hu, Yanjun","Lang, Chunhui","Huang, Daoqiu","Sun, Qiuyan","Xiong, Yan","Huang, Xia","Lv, Jinglong","Luo, Yaling","Shen, Li","Yang, Haoran","Huang, Gu","Yang, Ruishan","32198776"],"abstract":["The outbreak of the novel coronavirus in China (SARS-CoV-2) that began in December 2019 presents a significant and urgent threat to global health. This study was conducted to provide the international community with a deeper understanding of this new infectious disease. Epidemiological, clinical features, laboratory findings, radiological characteristics, treatment, and clinical outcomes of 135 patients in northeast Chongqing were collected and analyzed in this study. A total of 135 hospitalized patients with COVID-19 were enrolled. The median age was 47 years (interquartile range, 36-55), and there was no significant gender difference (53.3% men). The majority of patients had contact with people from the Wuhan area. Forty-three (31.9%) patients had underlying disease, primarily hypertension (13 [9.6%]), diabetes (12 [8.9%]), cardiovascular disease (7 [5.2%]), and malignancy (4 [3.0%]). Common symptoms included fever (120 [88.9%]), cough (102 [76.5%]), and fatigue (44 [32.5%]). Chest computed tomography scans showed bilateral patchy shadows or ground glass opacity in the lungs of all the patients. All patients received antiviral therapy (135 [100%]) (Kaletra and interferon were both used), antibacterial therapy (59 [43.7%]), and corticosteroids (36 [26.7%]). In addition, many patients received traditional Chinese medicine (TCM) (124 [91.8%]). It is suggested that patients should receive Kaletra early and should be treated by a combination of Western and Chinese medicines. Compared to the mild cases, the severe ones had lower lymphocyte counts and higher plasma levels of Pt, APTT, d-dimer, lactate dehydrogenase, PCT, ALB, C-reactive protein, and aspartate aminotransferase. This study demonstrates the clinic features and therapies of 135 COVID-19 patients. Kaletra and TCM played an important role in the treatment of the viral pneumonia. Further studies are required to explore the role of Kaletra and TCM in the treatment of COVID-19."],"journal":"J Med Virol","authors":["Wan, Suxin","Xiang, Yi","Fang, Wei","Zheng, Yu","Li, Boqun","Hu, Yanjun","Lang, Chunhui","Huang, Daoqiu","Sun, Qiuyan","Xiong, Yan","Huang, Xia","Lv, Jinglong","Luo, Yaling","Shen, Li","Yang, Haoran","Huang, Gu","Yang, Ruishan"],"date":"2020-03-22T11:00:00Z","year":2020,"_id":"32198776","source":"PubMed","week":"202012|Mar 16 - Mar 22","doi":"10.1002/jmv.25783","keywords":["covid-19","clinical features","cognition","northeast chongqing","treatment"],"locations":["China","Chongqing","Wuhan","Chinese","Western","Chinese","Chongqing"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment","Diagnosis"],"weight":1,"_version_":1666138490096582656,"score":232.44089},{"pmid":32304402,"pmcid":"PMC7173027","title":"The performance of chest CT in evaluating the clinical severity of COVID-19 pneumonia: identifying critical cases based on CT characteristics.","text":["The performance of chest CT in evaluating the clinical severity of COVID-19 pneumonia: identifying critical cases based on CT characteristics.","OBJECTIVES: To assess the clinical severity of COVID-19 pneumonia using qualitative and/or quantitative chest CT indicators and identify the CT characteristics of critical cases. MATERIALS AND METHODS: Fifty-one patients with COVID-19 pneumonia including ordinary cases (group A, n=12), severe cases(group B, n=15) and critical cases (group C, n=24) were retrospectively enrolled. The qualitative and quantitative indicators from chest CT were recorded and compared using Fisher's exact test, one-way ANOVA, Kruskal-Wallis H test and receiver operating characteristic analysis. RESULTS: Depending on the severity of the disease, the number of involved lung segments and lobes, the frequencies of consolidation, crazy-paving pattern and air bronchogram increased in more severe cases. Qualitative indicators including total severity score for the whole lung and total score for crazy-paving and consolidation could distinguish groups B and C from A(69% sensitivity, 83% specificity and 73% accuracy) but were similar between group B and group C. Combined qualitative and quantitative indicators could distinguish these three groups with high sensitivity(B+C vs. A, 90%; C vs. B, 92%), specificity(100%, 87%) and accuracy(92%, 90%). Critical cases had higher total severity score(>10) and higher total score for crazy-paving and consolidation(>4) than ordinary cases, and had higher mean lung density(>-779HU) and full width at half maximum(>128HU) but lower relative volume of normal lung density(<==50%) than ordinary/severe cases. In our critical cases, eight patients with relative volume of normal lung density smaller than 40% received mechanical ventilation for supportive treatment, and two of them had died. CONCLUSION: A rapid, accurate severity assessment of COVID-19 pneumonia based on chest CT would be feasible and could provide help for making management decisions, especially for the critical cases.","Invest Radiol","Lyu, Peijie","Liu, Xing","Zhang, Rui","Shi, Lei","Gao, Jianbo","32304402"],"abstract":["OBJECTIVES: To assess the clinical severity of COVID-19 pneumonia using qualitative and/or quantitative chest CT indicators and identify the CT characteristics of critical cases. MATERIALS AND METHODS: Fifty-one patients with COVID-19 pneumonia including ordinary cases (group A, n=12), severe cases(group B, n=15) and critical cases (group C, n=24) were retrospectively enrolled. The qualitative and quantitative indicators from chest CT were recorded and compared using Fisher's exact test, one-way ANOVA, Kruskal-Wallis H test and receiver operating characteristic analysis. RESULTS: Depending on the severity of the disease, the number of involved lung segments and lobes, the frequencies of consolidation, crazy-paving pattern and air bronchogram increased in more severe cases. Qualitative indicators including total severity score for the whole lung and total score for crazy-paving and consolidation could distinguish groups B and C from A(69% sensitivity, 83% specificity and 73% accuracy) but were similar between group B and group C. Combined qualitative and quantitative indicators could distinguish these three groups with high sensitivity(B+C vs. A, 90%; C vs. B, 92%), specificity(100%, 87%) and accuracy(92%, 90%). Critical cases had higher total severity score(>10) and higher total score for crazy-paving and consolidation(>4) than ordinary cases, and had higher mean lung density(>-779HU) and full width at half maximum(>128HU) but lower relative volume of normal lung density(<==50%) than ordinary/severe cases. In our critical cases, eight patients with relative volume of normal lung density smaller than 40% received mechanical ventilation for supportive treatment, and two of them had died. CONCLUSION: A rapid, accurate severity assessment of COVID-19 pneumonia based on chest CT would be feasible and could provide help for making management decisions, especially for the critical cases."],"journal":"Invest Radiol","authors":["Lyu, Peijie","Liu, Xing","Zhang, Rui","Shi, Lei","Gao, Jianbo"],"date":"2020-04-19T11:00:00Z","year":2020,"_id":"32304402","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1097/RLI.0000000000000689","topics":["Diagnosis"],"weight":1,"_version_":1666138491115798530,"score":205.80731},{"pmid":32420751,"title":"Evaluation of the Adjuvant Efficacy of Natural Herbal Medicine on COVID-19: A Retrospective Matched Case-Control Study.","text":["Evaluation of the Adjuvant Efficacy of Natural Herbal Medicine on COVID-19: A Retrospective Matched Case-Control Study.","Since the outbreak of Corona Virus Disease 2019 (COVID-19) in Hubei province, the epidemic scale has increased rapidly, and no effective antiviral drug therapy has been identified yet. This study aimed to evaluate the adjuvant efficacy of Natural Herbal Medicine (NHM) combined with Western medicine in the treatment of COVID-19. We performed a retrospective, 1:1 matched, case-control study of the first cohort of hospitalized COVID-19-confirmed cases (January 17, 2020 to January 28, 2020). A total of 22 of the 36 confirmed patients were included in this study, split into two groups of 11: the NHM group (NHM combined standard Western medicine treatment) and control group (standard Western medicine treatment alone). All patients received appropriate supportive care and regular clinical and laboratory monitoring. Main evaluation indicators included improvement of clinical symptoms such as fever, cough and diarrhea after hospitalization; pathogen nucleic acid test result of respiratory tract and fecal specimens of the patient after hospitalization, and change of chest CT examination after hospitalization. The duration of fever in the NHM group (3.4+/-2.4 days) was significantly shorter than that in the control group (5.6+/-2.2 days) (p=0.03). During the whole hospitalization period, the number of cases with diarrhea in the NHM group (two cases) was less than that in the control group (eight cases) (p=0.03). Compared with the control group (7.5+/-1.6), the duration for improvement (DI) of chest CT in the NHM group (5.6+/-2.3) was significantly shorter (p=0.04). Our results suggest that NHM could improve the clinical symptoms of COVID-19 patients and may be effective in treating COVID-19; thus, a larger, prospective, randomized, controlled clinical trial should be conducted to further evaluate the adjuvant efficacy of NHM in the treatment of COVID-19.","Am J Chin Med","Zhang, Hai-Tao","Huang, Ming-Xing","Liu, Xi","Zheng, Xin-Chun","Li, Xing-Hua","Chen, Gong-Qi","Xia, Jin-Yu","Hong, Zhong-Si","32420751"],"abstract":["Since the outbreak of Corona Virus Disease 2019 (COVID-19) in Hubei province, the epidemic scale has increased rapidly, and no effective antiviral drug therapy has been identified yet. This study aimed to evaluate the adjuvant efficacy of Natural Herbal Medicine (NHM) combined with Western medicine in the treatment of COVID-19. We performed a retrospective, 1:1 matched, case-control study of the first cohort of hospitalized COVID-19-confirmed cases (January 17, 2020 to January 28, 2020). A total of 22 of the 36 confirmed patients were included in this study, split into two groups of 11: the NHM group (NHM combined standard Western medicine treatment) and control group (standard Western medicine treatment alone). All patients received appropriate supportive care and regular clinical and laboratory monitoring. Main evaluation indicators included improvement of clinical symptoms such as fever, cough and diarrhea after hospitalization; pathogen nucleic acid test result of respiratory tract and fecal specimens of the patient after hospitalization, and change of chest CT examination after hospitalization. The duration of fever in the NHM group (3.4+/-2.4 days) was significantly shorter than that in the control group (5.6+/-2.2 days) (p=0.03). During the whole hospitalization period, the number of cases with diarrhea in the NHM group (two cases) was less than that in the control group (eight cases) (p=0.03). Compared with the control group (7.5+/-1.6), the duration for improvement (DI) of chest CT in the NHM group (5.6+/-2.3) was significantly shorter (p=0.04). Our results suggest that NHM could improve the clinical symptoms of COVID-19 patients and may be effective in treating COVID-19; thus, a larger, prospective, randomized, controlled clinical trial should be conducted to further evaluate the adjuvant efficacy of NHM in the treatment of COVID-19."],"journal":"Am J Chin Med","authors":["Zhang, Hai-Tao","Huang, Ming-Xing","Liu, Xi","Zheng, Xin-Chun","Li, Xing-Hua","Chen, Gong-Qi","Xia, Jin-Yu","Hong, Zhong-Si"],"date":"2020-05-19T11:00:00Z","year":2020,"_id":"32420751","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1142/S0192415X20500391","keywords":["clinical study","corona virus disease 2019 (covid-19)","nature herbal medicine (nhm)","traditional chinese medicine","treatment approach"],"locations":["Hubei","Western"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1667159284495941632,"score":199.08179},{"pmid":32118615,"pmcid":"PMC7147273","title":"The Clinical and Chest CT Features Associated With Severe and Critical COVID-19 Pneumonia.","text":["The Clinical and Chest CT Features Associated With Severe and Critical COVID-19 Pneumonia.","OBJECTIVE: The aim of this study was to investigate the clinical and computed tomography (CT) features associated with severe and critical coronavirus disease 2019 (COVID-19) pneumonia. MATERIALS AND METHODS: Eighty-three patients with COVID-19 pneumonia including 25 severe/critical cases and 58 ordinary cases were enrolled. The chest CT images and clinical data of them were reviewed and compared. The risk factors associated with disease severity were analyzed. RESULTS: Compared with the ordinary patients, the severe/critical patients had older ages, higher incidence of comorbidities, cough, expectoration, chest pain, and dyspnea. The incidences of consolidation, linear opacities, crazy-paving pattern, and bronchial wall thickening in severe/critical patients were significantly higher than those of the ordinary patients. Besides, severe/critical patients showed higher incidences of lymph node enlargement, pericardial effusion, and pleural effusion than the ordinary patients. The CT scores of severe/critical patients were significantly higher than those of the ordinary patients (P < 0.001). Receiver operating characteristic curve showed that the sensitivity and specificity of CT score were 80.0% and 82.8%, respectively, for the discrimination of the 2 types. The clinical factors of age older than 50 years, comorbidities, dyspnea, chest pain, cough, expectoration, decreased lymphocytes, and increased inflammation indicators were risk factors for severe/critical COVID-19 pneumonia. Computed tomography findings of consolidation, linear opacities, crazy-paving pattern, bronchial wall thickening, high CT scores, and extrapulmonary lesions were features of severe/critical COVID-19 pneumonia. CONCLUSIONS: There are significant differences in clinical symptoms, laboratory examinations, and CT manifestations between the ordinary patients and the severe/critical patients. Many factors are related to the severity of the disease, which can help clinicians to judge the severity of the patient and evaluate the prognosis.","Invest Radiol","Li, Kunhua","Wu, Jiong","Wu, Faqi","Guo, Dajing","Chen, Linli","Fang, Zheng","Li, Chuanming","32118615"],"abstract":["OBJECTIVE: The aim of this study was to investigate the clinical and computed tomography (CT) features associated with severe and critical coronavirus disease 2019 (COVID-19) pneumonia. MATERIALS AND METHODS: Eighty-three patients with COVID-19 pneumonia including 25 severe/critical cases and 58 ordinary cases were enrolled. The chest CT images and clinical data of them were reviewed and compared. The risk factors associated with disease severity were analyzed. RESULTS: Compared with the ordinary patients, the severe/critical patients had older ages, higher incidence of comorbidities, cough, expectoration, chest pain, and dyspnea. The incidences of consolidation, linear opacities, crazy-paving pattern, and bronchial wall thickening in severe/critical patients were significantly higher than those of the ordinary patients. Besides, severe/critical patients showed higher incidences of lymph node enlargement, pericardial effusion, and pleural effusion than the ordinary patients. The CT scores of severe/critical patients were significantly higher than those of the ordinary patients (P < 0.001). Receiver operating characteristic curve showed that the sensitivity and specificity of CT score were 80.0% and 82.8%, respectively, for the discrimination of the 2 types. The clinical factors of age older than 50 years, comorbidities, dyspnea, chest pain, cough, expectoration, decreased lymphocytes, and increased inflammation indicators were risk factors for severe/critical COVID-19 pneumonia. Computed tomography findings of consolidation, linear opacities, crazy-paving pattern, bronchial wall thickening, high CT scores, and extrapulmonary lesions were features of severe/critical COVID-19 pneumonia. CONCLUSIONS: There are significant differences in clinical symptoms, laboratory examinations, and CT manifestations between the ordinary patients and the severe/critical patients. Many factors are related to the severity of the disease, which can help clinicians to judge the severity of the patient and evaluate the prognosis."],"journal":"Invest Radiol","authors":["Li, Kunhua","Wu, Jiong","Wu, Faqi","Guo, Dajing","Chen, Linli","Fang, Zheng","Li, Chuanming"],"date":"2020-03-03T11:00:00Z","year":2020,"_id":"32118615","source":"PubMed","week":"202010|Mar 02 - Mar 08","doi":"10.1097/RLI.0000000000000672","topics":["Diagnosis","Mechanism"],"weight":1,"_version_":1666138490748796928,"score":198.20364},{"pmid":32224151,"title":"Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China.","text":["Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China.","BACKGROUND: Cancer patients are regarded as a highly vulnerable group in the current Coronavirus Disease 2019 (COVID-19) pandemic. To date, the clinical characteristics of COVID-19-infected cancer patients remain largely unknown. PATIENTS AND METHODS: In this retrospective cohort study, we included cancer patients with laboratory-confirmed COVID-19 from three designated hospitals in Wuhan, China. Clinical data were collected from medical records from 13 January 2020 to 26 February 2020. Univariate and multivariate analyses were carried out to assess the risk factors associated with severe events defined as a condition requiring admission to an intensive care unit, the use of mechanical ventilation, or death. RESULTS: A total of 28 COVID-19-infected cancer patients were included; 17 (60.7%) patients were male. Median (interquartile range) age was 65.0 (56.0-70.0) years. Lung cancer was the most frequent cancer type (n = 7; 25.0%). Eight (28.6%) patients were suspected to have hospital-associated transmission. The following clinical features were shown in our cohort: fever (n = 23, 82.1%), dry cough (n = 22, 81%), and dyspnoea (n = 14, 50.0%), along with lymphopaenia (n = 23, 82.1%), high level of high-sensitivity C-reactive protein (n = 23, 82.1%), anaemia (n = 21, 75.0%), and hypoproteinaemia (n = 25, 89.3%). The common chest computed tomography (CT) findings were ground-glass opacity (n = 21, 75.0%) and patchy consolidation (n = 13, 46.3%). A total of 15 (53.6%) patients had severe events and the mortality rate was 28.6%. If the last antitumour treatment was within 14 days, it significantly increased the risk of developing severe events [hazard ratio (HR) = 4.079, 95% confidence interval (CI) 1.086-15.322, P = 0.037]. Furthermore, patchy consolidation on CT on admission was associated with a higher risk of developing severe events (HR = 5.438, 95% CI 1.498-19.748, P = 0.010). CONCLUSIONS: Cancer patients show deteriorating conditions and poor outcomes from the COVID-19 infection. It is recommended that cancer patients receiving antitumour treatments should have vigorous screening for COVID-19 infection and should avoid treatments causing immunosuppression or have their dosages decreased in case of COVID-19 coinfection.","Ann Oncol","Zhang, L","Zhu, F","Xie, L","Wang, C","Wang, J","Chen, R","Jia, P","Guan, H Q","Peng, L","Chen, Y","Peng, P","Zhang, P","Chu, Q","Shen, Q","Wang, Y","Xu, S Y","Zhao, J P","Zhou, M","32224151"],"abstract":["BACKGROUND: Cancer patients are regarded as a highly vulnerable group in the current Coronavirus Disease 2019 (COVID-19) pandemic. To date, the clinical characteristics of COVID-19-infected cancer patients remain largely unknown. PATIENTS AND METHODS: In this retrospective cohort study, we included cancer patients with laboratory-confirmed COVID-19 from three designated hospitals in Wuhan, China. Clinical data were collected from medical records from 13 January 2020 to 26 February 2020. Univariate and multivariate analyses were carried out to assess the risk factors associated with severe events defined as a condition requiring admission to an intensive care unit, the use of mechanical ventilation, or death. RESULTS: A total of 28 COVID-19-infected cancer patients were included; 17 (60.7%) patients were male. Median (interquartile range) age was 65.0 (56.0-70.0) years. Lung cancer was the most frequent cancer type (n = 7; 25.0%). Eight (28.6%) patients were suspected to have hospital-associated transmission. The following clinical features were shown in our cohort: fever (n = 23, 82.1%), dry cough (n = 22, 81%), and dyspnoea (n = 14, 50.0%), along with lymphopaenia (n = 23, 82.1%), high level of high-sensitivity C-reactive protein (n = 23, 82.1%), anaemia (n = 21, 75.0%), and hypoproteinaemia (n = 25, 89.3%). The common chest computed tomography (CT) findings were ground-glass opacity (n = 21, 75.0%) and patchy consolidation (n = 13, 46.3%). A total of 15 (53.6%) patients had severe events and the mortality rate was 28.6%. If the last antitumour treatment was within 14 days, it significantly increased the risk of developing severe events [hazard ratio (HR) = 4.079, 95% confidence interval (CI) 1.086-15.322, P = 0.037]. Furthermore, patchy consolidation on CT on admission was associated with a higher risk of developing severe events (HR = 5.438, 95% CI 1.498-19.748, P = 0.010). CONCLUSIONS: Cancer patients show deteriorating conditions and poor outcomes from the COVID-19 infection. It is recommended that cancer patients receiving antitumour treatments should have vigorous screening for COVID-19 infection and should avoid treatments causing immunosuppression or have their dosages decreased in case of COVID-19 coinfection."],"journal":"Ann Oncol","authors":["Zhang, L","Zhu, F","Xie, L","Wang, C","Wang, J","Chen, R","Jia, P","Guan, H Q","Peng, L","Chen, Y","Peng, P","Zhang, P","Chu, Q","Shen, Q","Wang, Y","Xu, S Y","Zhao, J P","Zhou, M"],"date":"2020-04-01T11:00:00Z","year":2020,"_id":"32224151","source":"PubMed","week":"202014|Mar 30 - Apr 05","doi":"10.1016/j.annonc.2020.03.296","keywords":["covid-19","cancer","retrospective case study","severe clinical events"],"locations":["Wuhan","China","Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis","Treatment"],"weight":1,"_version_":1666138492471607296,"score":193.50076}]}